by The global inhaled nitric oxide delivery systems market size is expected to be worth around US$ 530.2 million by 2030, according to a new report by Vision Research Reports.
The global inhaled nitric oxide delivery systems market size was valued at US$ 260.5 million in 2020 and is anticipated to grow at a CAGR of 7.9% during forecast period 2021 to 2030.
Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/38877
Table of Contents
Inhaled Nitric Oxide Delivery Systems Market Growth Factors
A rise in the cases of respiratory failure among neonates, increased pollution levels leading to lung diseases in adults, need for quick treatment response, and reduced complications are the factors driving the adoption of inhaled nitric oxide therapy. The presence of several small-scale manufacturers and research initiatives undertaken by major players to prove treatment efficacy against the SARS-CoV-2 virus further enhances market growth.
Safe and effective treatment regimen, a rapid offset of action, reduced toxicity, high concentration of drug at the target organ, avoidance of systemic adverse reaction, and reduced dose of medication are some of the advantages of INO over other medications.
Inhaled Nitric Oxide Delivery Systems Market Report Coverage
| Report Scope | Details |
| Market Size | USD 530.2 million by 2030 |
| Growth Rate | CAGR of 7.9% From 2021 to 2030 |
| Base Year | 2021 |
| Forecast Period | 2021 to 2030 |
| Segments Covered | Type, application, product, end user |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies Mentioned | Mallinckrodt Pharmaceuticals; Getinge; Vero Biotech; LINDE; Beyond Air; SLE; NU MED; Bellerophon Therapeutics; Air Liquide Healthcare; Circassia Pharmaceuticals |
By Type Analysis
The pediatric segment accounted for the largest revenue share of 77.6% in 2020. Inhaled nitric oxide is proved to be the most effective in treating neonatal diseases like Hypoxic Respiratory Failure (HRF).
low cost of raw materials, abundant resource availability, and a large consumer base, are also anticipated to boost segment growth. INO delivery devices are priced at USD 1400-1700, which makes it difficult for low-tier end-user settings to adopt such equipment as they focus on minimizing the bills.
By End-user Analysis
The hospitals segment captured the highest revenue share of 87.2% in 2020 owing to the ease of delivery, ability to liquidate for establishing INO delivery device and monitor system, a large number of staff to track device operations, and presence of emergency department.
Mortality rates due to ARFare around 30% in the world. Hence, it is essential to provide these patients with life support and critical care, such as that in hospital ICUs. A rise in the number of hospital admissions is leading to the growth of this segment
By Regional Analysis
North America is expected to be the fastest-growing regional market registering a CAGR of 7.84% during the forecast period. This growth can mainly be attributed to the increasing incidences of neonatal mortality due to the rising cases of HRF.
APAC held the largest revenue share in 2020 and will continue the trend during the forecast period due to the growing pediatric population, a rise in the number of patients suffering from respiratory failure, and the presence of local manufacturers of nitric oxide disposables & systems.
Read also @ E-Clinical Solutions Market Estimated to Cross US$ 22.7 Bn by 2030
Major Key Players Covered in The Inhaled Nitric Oxide Delivery Systems Market Report include
- Mallinckrodt Pharmaceuticals
- Getinge
- Vero Biotech
- LINDE
- Beyond Air
- SLE
- NU MED
- Bellerophon Therapeutics
- Air Liquide Healthcare
- Circassia Pharmaceuticals
Inhaled Nitric Oxide Delivery Systems Market Segmentation
- By Type
- Pediatrics
- Adult
- By Application
- Hypoxic Respiratory Failure (HRF)
- Acute Hypoxemic Respiratory Failure (AHRF)
- Others
- By Product
- Disposables
- System
- By End-user
- Hospitals
- Ambulatory Centers
- Clinics
- Regional
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Italy
- Spain
- Norway
- Sweden
- Russia
- Asia Pacific
- Japan
- China
- India
- Thailand
- South Korea
- Australia
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Turkey
- North America
Table of Contents
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Inhaled Nitric Oxide Delivery Systems Market Snapshot
Chapter 4. Inhaled Nitric Oxide Delivery Systems Market Variables and Scope
4.1. Introduction
4.2. Inhaled Nitric Oxide Delivery Systems Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Product Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Inhaled Nitric Oxide Delivery Systems Market Dynamics Analysis and Trends
5.1. Inhaled Nitric Oxide Delivery Systems Market Dynamics
5.1.1. Inhaled Nitric Oxide Delivery Systems Market Drivers
5.1.2. Inhaled Nitric Oxide Delivery Systems Market Restraints
5.1.3. Inhaled Nitric Oxide Delivery Systems Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Inhaled Nitric Oxide Delivery Systems Market, By Type
7.1. Inhaled Nitric Oxide Delivery Systems Market, by Type, 2021-2030
7.1.1. Pediatrics
7.1.1.1. Market Revenue and Forecast (2017-2030)
7.1.2. Adult
7.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 8. Global Inhaled Nitric Oxide Delivery Systems Market, By Application
8.1. Inhaled Nitric Oxide Delivery Systems Market, by Application, 2021-2030
8.1.1. Hypoxic Respiratory Failure (HRF)
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Acute Hypoxemic Respiratory Failure (AHRF)
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Others
8.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Inhaled Nitric Oxide Delivery Systems Market, By Product
9.1. Inhaled Nitric Oxide Delivery Systems Market, by Product, 2021-2030
9.1.1. Disposables
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. System
9.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Inhaled Nitric Oxide Delivery Systems Market, By End-user
10.1. Inhaled Nitric Oxide Delivery Systems Market, by End-user, 2021-2030
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Ambulatory Centers
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Clinics
10.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Inhaled Nitric Oxide Delivery Systems Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Type (2017-2030)
11.1.2. Market Revenue and Forecast, by Application (2017-2030)
11.1.3. Market Revenue and Forecast, by Product (2017-2030)
11.1.4. Market Revenue and Forecast, by End-user (2017-2030)
11.1.5. U.S.
11.1.5.1. Market Revenue and Forecast, by Type (2017-2030)
11.1.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.1.5.3. Market Revenue and Forecast, by Product (2017-2030)
11.1.5.4. Market Revenue and Forecast, by End-user (2017-2030)
11.1.6. Rest of North America
11.1.6.1. Market Revenue and Forecast, by Type (2017-2030)
11.1.6.2. Market Revenue and Forecast, by Application (2017-2030)
11.1.6.3. Market Revenue and Forecast, by Product (2017-2030)
11.1.6.4. Market Revenue and Forecast, by End-user (2017-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Type (2017-2030)
11.2.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.3. Market Revenue and Forecast, by Product (2017-2030)
11.2.4. Market Revenue and Forecast, by End-user (2017-2030)
11.2.5. UK
11.2.5.1. Market Revenue and Forecast, by Type (2017-2030)
11.2.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.5.3. Market Revenue and Forecast, by Product (2017-2030)
11.2.5.4. Market Revenue and Forecast, by End-user (2017-2030)
11.2.6. Germany
11.2.6.1. Market Revenue and Forecast, by Type (2017-2030)
11.2.6.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.6.3. Market Revenue and Forecast, by Product (2017-2030)
11.2.6.4. Market Revenue and Forecast, by End-user (2017-2030)
11.2.7. France
11.2.7.1. Market Revenue and Forecast, by Type (2017-2030)
11.2.7.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.7.3. Market Revenue and Forecast, by Product (2017-2030)
11.2.7.4. Market Revenue and Forecast, by End-user (2017-2030)
11.2.8. Rest of Europe
11.2.8.1. Market Revenue and Forecast, by Type (2017-2030)
11.2.8.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.8.3. Market Revenue and Forecast, by Product (2017-2030)
11.2.8.4. Market Revenue and Forecast, by End-user (2017-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Type (2017-2030)
11.3.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.3. Market Revenue and Forecast, by Product (2017-2030)
11.3.4. Market Revenue and Forecast, by End-user (2017-2030)
11.3.5. India
11.3.5.1. Market Revenue and Forecast, by Type (2017-2030)
11.3.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.5.3. Market Revenue and Forecast, by Product (2017-2030)
11.3.5.4. Market Revenue and Forecast, by End-user (2017-2030)
11.3.6. China
11.3.6.1. Market Revenue and Forecast, by Type (2017-2030)
11.3.6.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.6.3. Market Revenue and Forecast, by Product (2017-2030)
11.3.6.4. Market Revenue and Forecast, by End-user (2017-2030)
11.3.7. Japan
11.3.7.1. Market Revenue and Forecast, by Type (2017-2030)
11.3.7.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.7.3. Market Revenue and Forecast, by Product (2017-2030)
11.3.7.4. Market Revenue and Forecast, by End-user (2017-2030)
11.3.8. Rest of APAC
11.3.8.1. Market Revenue and Forecast, by Type (2017-2030)
11.3.8.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.8.3. Market Revenue and Forecast, by Product (2017-2030)
11.3.8.4. Market Revenue and Forecast, by End-user (2017-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Type (2017-2030)
11.4.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.3. Market Revenue and Forecast, by Product (2017-2030)
11.4.4. Market Revenue and Forecast, by End-user (2017-2030)
11.4.5. GCC
11.4.5.1. Market Revenue and Forecast, by Type (2017-2030)
11.4.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.5.3. Market Revenue and Forecast, by Product (2017-2030)
11.4.5.4. Market Revenue and Forecast, by End-user (2017-2030)
11.4.6. North Africa
11.4.6.1. Market Revenue and Forecast, by Type (2017-2030)
11.4.6.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.6.3. Market Revenue and Forecast, by Product (2017-2030)
11.4.6.4. Market Revenue and Forecast, by End-user (2017-2030)
11.4.7. South Africa
11.4.7.1. Market Revenue and Forecast, by Type (2017-2030)
11.4.7.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.7.3. Market Revenue and Forecast, by Product (2017-2030)
11.4.7.4. Market Revenue and Forecast, by End-user (2017-2030)
11.4.8. Rest of MEA
11.4.8.1. Market Revenue and Forecast, by Type (2017-2030)
11.4.8.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.8.3. Market Revenue and Forecast, by Product (2017-2030)
11.4.8.4. Market Revenue and Forecast, by End-user (2017-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Type (2017-2030)
11.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.5.3. Market Revenue and Forecast, by Product (2017-2030)
11.5.4. Market Revenue and Forecast, by End-user (2017-2030)
11.5.5. Brazil
11.5.5.1. Market Revenue and Forecast, by Type (2017-2030)
11.5.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.5.5.3. Market Revenue and Forecast, by Product (2017-2030)
11.5.5.4. Market Revenue and Forecast, by End-user (2017-2030)
11.5.6. Rest of LATAM
11.5.6.1. Market Revenue and Forecast, by Type (2017-2030)
11.5.6.2. Market Revenue and Forecast, by Application (2017-2030)
11.5.6.3. Market Revenue and Forecast, by Product (2017-2030)
11.5.6.4. Market Revenue and Forecast, by End-user (2017-2030)
Chapter 12. Company Profiles
12.1. Mallinckrodt Pharmaceuticals
12.1.1. Company Overview
12.1.2. Type Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Getinge
12.2.1. Company Overview
12.2.2. Type Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Vero Biotech
12.3.1. Company Overview
12.3.2. Type Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. LINDE
12.4.1. Company Overview
12.4.2. Type Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Beyond Air
12.5.1. Company Overview
12.5.2. Type Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. SLE
12.6.1. Company Overview
12.6.2. Type Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. NU MED
12.7.1. Company Overview
12.7.2. Type Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Bellerophon Therapeutics
12.8.1. Company Overview
12.8.2. Type Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Air Liquide Healthcare
12.9.1. Company Overview
12.9.2. Type Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Circassia Pharmaceuticals
12.10.1. Company Overview
12.10.2. Type Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
Glossary of Terms
Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38877
Contact Us:
Vision Research Reports
Call: +1 9197 992 333
